Citi raised the firm’s price target on Sarepta (SRPT) to $9 from $8 and keeps a Sell rating on the shares. The firm updated the company’s model post the Q4 report.
Claim 55% Off TipRanks
New trading tool for SRPT bullsPublished first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRPT:
- Controversial Prasad leaving FDA, NYT reports
- Sarepta Therapeutics’ 2025 Restructuring Plan Faces High Execution Risk Amid Deep Job Cuts and Cost-Saving Uncertainty
- Sarepta Therapeutics Eyes 2026 Reset After Rocky Year
- Sarepta price target lowered to $29 from $34 at Wedbush
- Sarepta price target lowered to $38 from $45 at Wells Fargo